Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation

Trial Profile

A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2018

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 12 Sep 2018 Planned End Date changed from 30 May 2021 to 31 May 2021.
    • 04 Jun 2018 Planned End Date changed from 26 Mar 2021 to 30 May 2021.
    • 04 Jun 2018 Planned primary completion date changed from 2 Jul 2020 to 4 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top